Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib

BACKGROUND: Although anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have impressive response in advanced lung adenocarcinoma with anaplastic lymphoma kinase (ALK) fusion, no guidelines point to the potential benefits of neoadjuvant ALK-TKIs for N3 unresectable locally advanced lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Xiaoqian, Wang, Ting, Lin, Yiyun, Zhang, Jiabi, Wang, Yuqing, Wang, Weiya, Zhou, Qinghua, Zhu, Daxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095823/
https://www.ncbi.nlm.nih.gov/pubmed/37064118
http://dx.doi.org/10.3389/fonc.2023.1104910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095823/
https://www.ncbi.nlm.nih.gov/pubmed/37064118
http://dx.doi.org/10.3389/fonc.2023.1104910

Ejemplares similares